S. Chandarlapaty

The paper identifies TP53 loss and MDM2 amplification as factors associated with poor long-term response to CDK4/6 inhibition in breast cancer and shows that CDK2 inhibition can overcome this resistance.

The paper analyzes genomic data from 25,000 patients to identify associations between genomic alterations and metastatic patterns across 50 tumor types, finding chromosomal instability correlates with metastatic burden in some cancers.

The paper identifies ER-LBD, a novel estrogen receptor alpha isoform, which promotes breast cancer growth and resistance to endocrine therapy.

The paper identifies actionable genomic vulnerabilities in cancer by analyzing driver alteration co-occurrence patterns and validates predictions in mice, improving drug response modeling from patient data.

This study shows that bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells by inhibiting Y537S and D538G ER mutants more effectively than tamoxifen.